The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.
Olaparib Combo Approaches EU Approval for Select Patients With mCRPCNovember 14th 2022
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of olaparib in combination with abiraterone acetate and prednisone or prednisolone for use in adult patients with metastatic castration-resistant prostate cancer in whom chemotherapy is not indicated.
Prostate Cancer Has High Rate of Actionable Mutations, Underscoring Need for TestingNovember 12th 2022
All patients with prostate cancer, except for those with low-risk or very low-risk localized disease, should be tested for germline mutations, and somatic testing should be done in all patients with metastatic disease as there are therapeutic implications.
Sequencing Considerations in mCRPC Treatment Grow Increasingly ComplexNovember 11th 2022
For patients with metastatic castration-resistant prostate cancer who experience disease progression on novel hormonal agents (NHAs) and androgen deprivation therapy, it is important to consider when the NHA was received and whether docetaxel has been administered, as these factors affect downstream options and sequencing.
Genetic Testing Proves Significant in Identifying Somatic and Germline Mutations in Prostate CancerNovember 11th 2022
As the role of genetic testing in clinical practice becomes more prevalent for patients with prostate cancer to identify mutations, physicians must consider a variety of factors to determine which patients are candidates for somatic and/or germline testing.
ADT Alone, With Docetaxel Is Not Enough: ADT Intensification Is SOC for Metastatic Castration-sensitive Prostate CancerNovember 11th 2022
Because androgen deprivation therapy alone or with docetaxel is not recommended for most patients with metastatic castration-sensitive prostate cancer, a decision must be made between leveraging couplets vs triplets.
Dr. Antonarakis on Therapeutic Agents for Select Patients With mCRPCNovember 11th 2022
Emmanuel Antonarakis, MD, discusses the different therapeutic agents that are available for patients with metastatic castration-resistant prostate cancer who display either somatic or germline mutations.
Dr. Wee on the Current Landscape of Nonmetastatic CRPC Treatment and ClassificationOctober 31st 2022
Christopher Wee, MD discusses the current treatment landscape for nonmetastatic castration-resistant prostate cancer, and how the success of new diagnostic tools decreases the need for this classification.
Darolutamide Combination Improves OS vs Placebo in Black Patients With mHSPCOctober 28th 2022
Darolutamide plus androgen-deprivation therapy and docetaxel elicited an overall survival benefit over placebo plus ADT and docetaxel in Black and African American patients with metastatic hormone-sensitive prostate cancer similar to the benefit observed in the overall population of the ARASENS trial.
Radiation Plus Intermittent Hormone Therapy Improves PFS in Oligometastatic Prostate CancerOctober 27th 2022
A regimen comprised of radiation and intermittent hormone therapy (HT) resulted in an improvement in progression-free survival in patients with oligometastatic prostate cancer, according to data from the phase 2 EXTEND trial.
Cediranib Plus Olaparib Elicits rPFS Benefit in Metastatic Castration-Resistant Prostate CancerOctober 24th 2022
The combination of cediranib and olaparib significantly improved radiographic progression-free survival compared with olaparib monotherapy in patients with metastatic castration-resistant prostate cancer.
Pluvicto Receives Support for European Approval in PSMA-Positive mCRPCOctober 14th 2022
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of Lutetium 177 vipivotide tetraxetan in combination with androgen deprivation therapy with or without androgen receptor pathway inhibition for the treatment of adult patients with progressive prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer who have been treated with AR pathway inhibition and taxane-based chemotherapy.
Novel AR-Targeted Therapies for Metastatic Hormone-Sensitive Prostate Cancer: Which One to ChooseOctober 5th 2022
Advances in the understanding of the genomics and biological functions of prostate cancer have resulted in the emergence of several new classes of agents that have improved outcomes in men with prostate cancer, including metastatic hormone-sensitive prostate cancer.
Talazoparib/Enzalutamide Combo Meets rPFS End Point in Untreated Metastatic CRPCOctober 4th 2022
The addition of talazoparib to enzalutamide produced a statistically significant and clinically meaningful improvement in radiographic progression-free survival vs enzalutamide plus placebo in previously untreated patients with metastatic castration-resistant prostate cancer, with or without homologous recombination repair gene mutations.
Rucaparib Meets rPFS End Point in BRCA/ATM-Mutated mCRPCOctober 3rd 2022
Single-agent rucaparib significantly improved radiographic progression-free survival vs chemotherapy or second-line androgen deprivation therapy in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer harboring BRCA or ATM mutations.
FDA Accepts NDA for 18F-rhPSMA-7.3 as Diagnostic Imaging Tool in Prostate CancerSeptember 29th 2022
The FDA has accepted for review a new drug application for 18F-rhPSMA-7.3, an investigational radiohybrid PSMA-targeted PET imaging agent for diagnostic imaging of prostate cancer, according to an announcement from Blue Earth Diagnostics.